Cerveau Technologies Inc.
60 State Street
Suite 700
Boston
Massachusetts
02109
United States
Tel: 617-610-5828
Website: http://cerveautechnologies.com
About Cerveau Technologies Inc.
Cerveau Technologies, Inc. is a partnership between Enigma Biomedical Group, Inc. and Sinotau Pharmaceutical Group. Cerveau's vision is to globally develop diagnostics and technology that positively impact patients with neurodegenerative disorders including Alzheimer's disease.LEADERSHIP:
President: Rick Hiatt
35 articles about Cerveau Technologies Inc.
-
Cerveau Technologies Inc. and Prothena Sign Agreement to Provide Novel Tau Imaging Biomarker for Research and Development of Investigational Therapeutics for Neurodegenerative Diseases
1/10/2023
Cerveau Technologies, Inc. today announced a research collaboration agreement with Othair Prothena Limited, a subsidiary of Prothena Corporation plc (Prothena), which will enable Prothena to use Cerveau’s [F-18]MK-6240, an investigational imaging agent, in Positron Emission Tomography (PET) scans to assess the status and progression of neurofibrillary tangles (NFTs) in the brain.
-
Cerveau Technologies Inc. and LEXEO Therapeutics, Inc.- Sign Agreement to Provide Novel Tau Imaging Biomarker for Disease Modifier Research
11/7/2022
Cerveau Technologies, Inc. announced a license agreement with LEXEO Therapeutics, Inc., which will enable LEXEO to use Cerveau’s [F-18]MK-6240, an investigational imaging agent, in Positron Emission Tomography scans to assess the status and progression of neurofibrillary tangles in the brain.
-
Cerveau Technologies Inc. and Alnylam® Pharmaceuticals Sign Agreement to Provide Novel Tau Imaging Biomarker for Disease Modifier Research
9/1/2022
Cerveau Technologies, Inc. announced a research collaboration agreement with Alnylam® Pharmaceuticals, which will enable Alnylam to use Cerveau’s [F-18]MK-6240, an investigational imaging agent, in Positron Emission Tomography scans to assess the status and progression of neurofibrillary tangles in the brain.
-
Cerveau Technologies Inc. Signs Agreement with Roche to Provide Novel Tau Imaging Biomarker for Disease Modifier Research
3/10/2022
Cerveau Technologies, Inc. announced a research collaboration agreement with Roche Products Limited, on the use of Cerveau’s [F-18]MK-6240, an investigational imaging agent, in Positron Emission Tomography scans to assess the status and progression of neurofibrillary tangles in the brain.
-
Cerveau Technologies, Inc. and Nihon Med-Physics Co., Ltd. Announce Manufacturing Service Agreement for [18F]MK-6240 in Japan
2/22/2022
Cerveau Technologies, Inc. (Cerveau) and Nihon Medi-Physics (NMP), a leading company for radiopharmaceuticals in Japan, today announced that they signed a manufacturing service agreement, in which Cerveau grants NMP the right to manufacture [18F]MK-6240, a next generation investigational Positron Emission Tomography (PET) imaging agent.
-
Cerveau Technologies, Inc. Announces Collaboration with University College of London
5/4/2020
Cerveau Technologies Inc. today announced a research collaboration with University College London (UCL), a leading UK academic center for the production and application of imaging biomarkers for use in clinical research, that grants the institution the right to manufacture [ 18 F]MK-6240, a next generation investigational Positron Emission Tomography (PET) imaging agent. The facility has been fully qualified by Cerveau to produce t
-
Cerveau Technologies, Inc. Announces Collaboration with Alector, Inc.
3/20/2020
Cerveau Technologies Inc. today announced a licensing agreement with Alector, in which Cerveau will provide its investigational imaging agent (MK-6240) to Alector for use in Positron Emission Tomography (PET) scans to assess the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs, made up of aggregated tau protein, are a hallmark of several neurodegenerative diseases, including Alzheimer’s disease. A
-
Cerveau Technologies, Inc. Announce Initiation of Japanese Phase I Study
11/14/2019
Cerveau Technologies, Inc. today announced that the first healthy volunteer was injected and scanned in the Japan Phase I study of [F18]MK-6240, an investigational imaging agent
-
Cerveau Technologies Inc. Signs Research Agreement with Takeda to Provide Novel Tau Imaging Agent
9/27/2019
Cerveau Technologies, Inc. announced a research collaboration agreement with Takeda Pharmaceutical Company Limited (Takeda), which will enable Takeda to use Cerveau’s [F-18]MK-6240, an investigational imaging agent, in Positron Emission Tomography (PET) scans to assess the status and progression of neurofibrillary tangles (NFTs) in the brain.
-
Cerveau Technologies, Inc. Announces a Partnership with LuMind IDSC Foundation to Study Accumulation of Neurofibrillary Tau in Down Syndrome
5/9/2019
Cerveau Technologies, Inc. today announced a research collaboration with the LuMind IDSC Foundation (LuMind IDSC) involving use of Cerveau’s investigational imaging agent (MK-6240) in a multicenter clinical trial aimed at assessing accumulation of misfolded tau protein in people with Down syndrome (DS)
-
Cerveau Technologies Inc. Signs Research Agreement with Eisai Inc., for Novel Tau Imaging Agent
3/22/2019
Cerveau Technologies, Inc. today announced a research collaboration agreement with Eisai Inc., which will enable Eisai to use Cerveau’s [F-18]MK-6240, an investigational imaging agent, in Positron Emission Tomography (PET) scans to assess the status and progression of neurofibrillary tangles (NFTs) in the brain.
-
Cerveau Technologies, Inc. and Institut de Radiofarmacia Aplicada de Barcelona, S.L. Announce Agreement to Manufacture Investigational Tau Ligand, [18F]MK-6240
2/19/2019
This week Institut de Radiofarmacia Aplicada de Barcelona, S.L., a leading producer of imaging biomarkers for use in clinical research, has signed an agreement that grants the company the right to manufacture [18F]MK-6240, a next generation investigational Positron Emission Tomography imaging agent.
-
Cerveau Technologies, Inc. to Support a First Clinical Study in Asia of a Novel Biomarker of Alzheimer’s Disease
12/13/2018
Cerveau Technologies Inc. today announced that the Memory Aging and Cognition Centre (MACC) at the National University Health System (NUHS) in Singapore has initiated a study with an early stage imaging agent [18F]MK-6240 to be used in Positron Emission Tomography (PET) scans for assessing the level and progression of neurofibrillary tangles (NFTs) in the brain.
-
Cerveau Technologies Inc. Announces Expanded Research Access to Novel Tau Imaging Agent
8/7/2018
This expansion has been driven by the increasing interest in [18F]MK-6240 as a developmental and investigational tool in clinical trials.
-
Cerveau Technologies, Inc. Signs Research Agreement with Tokyo Metropolitan Institute of Gerontology, Japan
5/15/2018
Cerveau Technologies Inc. today announced an agreement with the Tokyo Metropolitan Institute of Gerontology in Japan to support multiple projects over the next several years.
-
Navidea Signs Deal to Sublicense NAV4694 Worldwide Development Rights
4/16/2018
NAV4694 is a beta-amyloid imaging agent being evaluated as an aid in the differential diagnosis of early-onset Alzheimer’s disease
-
Cerveau Technologies, Inc. Signs Research Agreement with Massachusetts General Hospital
2/8/2018
Cerveau Technologies Inc. today announced an agreement with Massachusetts General Hospital (MGH) to support multiple projects over the next several years.
-
Cerveau Technologies, Inc. Signs Research Agreement with University of Pittsburgh
1/17/2018
Cerveau Technologies Inc. today announced an agreement with the University of Pittsburgh to support multiple projects over the next several years.
-
Cerveau Technologies Ink R&D Deal With KU Leuven University, Belgium
12/15/2017
The deal will support multiple projects over the next several years.
-
Cerveau Technologies Signs Research Agreement With VU Medical Center Amsterdam
12/6/2017
These research projects are for studies of an early stage imaging agent (MK-6240) to be used in Positron Emission Tomography (PET) scans for assessing the status and progression of neurofibrillary tangles (NFTs) in the brain.